Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY

A Study of Morab-202 Verses Investigator's Choice Chemotherapy in Female Participants With Platinum-resistants High grade Serous (Hgs) Ovarian, Primary, Peritoneal, Or Fallopian Tube Cancer

Am I eligible?
Phototherapy icon

Additional information about patient privacy incident

Learn more
Plaque psoriasis image

Overview

To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is essential to know the prevalence of HRD in women with advanced high-grade serous or endometrioid ovarian cancer. Presently, the prevalence data for HRD are available from selected geographies only and range from 31% to 50%. Furthermore, the risk factors associated with HRD and clinical characteristics of patients with HRD need exploration for region-specific differences.

Detailed Description

This cross-sectional, noninterventional, multicentre, epidemiological, observational study is designed to determine the prevalence of HRD in patients with newly diagnosed high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer. The study will also determine the prevalence of tBRCA1m/tBRCA2m, genomic instability, and identify the associated risk factors in several countries across broad geographic regions.

Eligibility:

Inclusion Criteria:

  • Patients ≥18 years of age or adults according to age of majority as defined by the local regulations;
  • Willing and able to provide written informed consent for participation in the study;
  • Patients with histologically confirmed new diagnosis (within past 120 days of enrolment) of high-grade (stage III or IV of FIGO classification 2014) serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer;
  • Patients having availability of histopathology report and FFPE archival tumour tissue block(s) collected within past 120 days of enrolment.
Exclusion Criteria:
  • Patients with mucinous, clear-cell, undifferentiated carcinoma or malignant Brenner's tumour;
  • Patients diagnosed with any severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results, and those in the judgment of the investigator are not appropriate for enrolment in this study 

Your Journey

01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.

Call (615) 344-9551 now to find out if you are eligible.